Yan-Ting Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan-Ting Liu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Jian Li
Department of Hematology, Peking Union Medical College Hospital, Beijing, China
4 shared publications - Lu Zhang
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 shared publications - Yu‐Han Gao
Department of Hematology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
4 shared publications - Miao-Yan Zhang
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 shared publications - Si‐Yuan Li
Department of Hematology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
3 shared publications - Hao Zhao
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1809
A Case Report of Acute Intermittent Porphyria Accompanied by Severe Peripheral Neuropathy
Background: Acute intermittent porphyria (AIP) is the most common and severe form of acute hepatic porphyria, caused by heterozygous mutations in the HMBS gene. Due to its non-specific clinical manifestations and low clinical awareness among clinicians, AIP is frequently misdiagnosed, leading to significant diagnostic delays and potentially fatal complications. Case presentation: We report a 20-year-old female patient who presented with a 9-month history of recurrent abdominal pain, paralytic ileus, unexplained liver injury, and hyponatremia, followed by progressive limb weakness. She was initially misdiagnosed with Guillain–Barré syndrome (GBS) and received intravenous immunoglobulin and systemic glucocorticoids. However, her condition deteriorated, and she developed life-threatening respiratory muscle paralysis requiring invasive mechanical ventilation. The diagnosis of AIP was confirmed by positive urinary porphobilinogen (PBG) testing and identification of the heterozygous HMBS c.517C>T pathogenic variant. The patient was treated with high-dose carbohydrate loading therapy and comprehensive supportive care, resulting in gradual clinical improvement. Discussion and Conclusions: This case exemplifies the substantial diagnostic challenges associated with AIP, especially when it manifests with peripheral neuropathy that closely mimics GBS. The triad of absent albuminocytologic dissociation in cerebrospinal fluid, preceding visceral symptoms, and inadequate response to standard first-line GBS therapy should immediately raise clinical suspicion for AIP. Enhanced clinical awareness of this rare disorder and timely implementation of urinary PBG screening are of paramount importance to prevent irreversible neurological complications and optimize long-term patient outcomes.
- 11 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1809
Open AccessA Case Report of Acute Intermittent Porphyria Accompanied by Severe Peripheral Neuropathy
Background: Acute intermittent porphyria (AIP) is the most common and severe form of acute hepatic porphyria, caused by heterozygous mutations in the HMBS gene. Due to its non-specific clinical manifestations and low clinical awareness among clinicians, AIP is frequently misdiagnosed, leading to significant diagnostic delays and potentially fatal complications. Case presentation: We report a 20-year-old female patient who presented with a 9-month history of recurrent abdominal pain, paralytic ileus, unexplained liver injury, and hyponatremia, followed by progressive limb weakness. She was initially misdiagnosed with Guillain–Barré syndrome (GBS) and received intravenous immunoglobulin and systemic glucocorticoids. However, her condition deteriorated, and she developed life-threatening respiratory muscle paralysis requiring invasive mechanical ventilation. The diagnosis of AIP was confirmed by positive urinary porphobilinogen (PBG) testing and identification of the heterozygous HMBS c.517C>T pathogenic variant. The patient was treated with high-dose carbohydrate loading therapy and comprehensive supportive care, resulting in gradual clinical improvement. Discussion and Conclusions: This case exemplifies the substantial diagnostic challenges associated with AIP, especially when it manifests with peripheral neuropathy that closely mimics GBS. The triad of absent albuminocytologic dissociation in cerebrospinal fluid, preceding visceral symptoms, and inadequate response to standard first-line GBS therapy should immediately raise clinical suspicion for AIP. Enhanced clinical awareness of this rare disorder and timely implementation of urinary PBG screening are of paramount importance to prevent irreversible neurological complications and optimize long-term patient outcomes.
- 29 December 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (4) , 1129-1135
Unicentric Castleman disease complicated with bronchiolitis obliterans: A single‐centre retrospective study from China
Summary: Bronchiolitis obliterans (BO) is a rare and life‐threatening complication of unicentric Castleman disease (UCD), which is considered the leading cause of death in UCD. However, few studies focused on the characteristics of UCD patients complicated with BO. This single‐centre, retrospective study of 281 patients diagnosed with UCD identified 18 patients (6.4%) with BO. UCD‐BO patients had a significantly lower age at UCD diagnosis than the UCD without BO group. 94.4% of UCD‐BO patients had deep lymph nodes involvement and 83.3% of them had paraneoplastic pemphigus, which were both significantly higher than UCD without BO. Median forced expiratory volume in 1 s of predicted was 20.9% (10%–41.9%) and 83.3% patients had severe BO. All patients underwent complete resection for UCD. 61.1% patients developed BO after surgery. UCD‐BO patients had a poorer overall survival than UCD without BO. Among severe BO, 11 patients did not receive lung transplantation and two of them died, with 62.5% (95% CI, 20.8%–100%) of estimated 5‐year overall survival. Four patients underwent lung transplantation and they all survived. UCD‐BO patients had distinct clinical identity. Complete resection could neither alleviate BO nor prevent BO progression. Lung transplantation is a vital treatment for improving prognosis for patients with severe BO.
- 29 December 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (4) , 1129-1135
Unicentric Castleman disease complicated with bronchiolitis obliterans: A single‐centre retrospective study from China
Summary: Bronchiolitis obliterans (BO) is a rare and life‐threatening complication of unicentric Castleman disease (UCD), which is considered the leading cause of death in UCD. However, few studies focused on the characteristics of UCD patients complicated with BO. This single‐centre, retrospective study of 281 patients diagnosed with UCD identified 18 patients (6.4%) with BO. UCD‐BO patients had a significantly lower age at UCD diagnosis than the UCD without BO group. 94.4% of UCD‐BO patients had deep lymph nodes involvement and 83.3% of them had paraneoplastic pemphigus, which were both significantly higher than UCD without BO. Median forced expiratory volume in 1 s of predicted was 20.9% (10%–41.9%) and 83.3% patients had severe BO. All patients underwent complete resection for UCD. 61.1% patients developed BO after surgery. UCD‐BO patients had a poorer overall survival than UCD without BO. Among severe BO, 11 patients did not receive lung transplantation and two of them died, with 62.5% (95% CI, 20.8%–100%) of estimated 5‐year overall survival. Four patients underwent lung transplantation and they all survived. UCD‐BO patients had distinct clinical identity. Complete resection could neither alleviate BO nor prevent BO progression. Lung transplantation is a vital treatment for improving prognosis for patients with severe BO.
- 1 May 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4223-4230
Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study
Refractory/relapsed idiopathic multicentric Castleman disease (R/R iMCD) has limited treatment options. With studies showing increased mTOR activation in iMCD patients, sirolimus becomes an attractive and promising therapy for R/R iMCD. Here we report the results of a retrospective study involving 26 R/R iMCD patients treated with sirolimus-containing regimen. The median age at sirolimus initiation was 40.5 years (23–60), with a median prior treatment line of 2 (1–5). 18 patients (69.2%) achieved symptomatic and biochemical response, with a median time to at least overall partial remission of 1.9 months (0.5–14.6). The median follow-up time from sirolimus initiation was 11.7 months (1.6–50.7) and the median time to next treatment (TTNT) was 46.2 months. No patients died at the end of follow-up. Most of the patients in the cohort are in ongoing responses and continue sirolimus therapy. Sirolimus is well tolerated with minor adverse effects. In conclusion, sirolimus is effective for R/R iMCD patients with good tolerance.
- 1 May 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4223-4230
Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study
Refractory/relapsed idiopathic multicentric Castleman disease (R/R iMCD) has limited treatment options. With studies showing increased mTOR activation in iMCD patients, sirolimus becomes an attractive and promising therapy for R/R iMCD. Here we report the results of a retrospective study involving 26 R/R iMCD patients treated with sirolimus-containing regimen. The median age at sirolimus initiation was 40.5 years (23–60), with a median prior treatment line of 2 (1–5). 18 patients (69.2%) achieved symptomatic and biochemical response, with a median time to at least overall partial remission of 1.9 months (0.5–14.6). The median follow-up time from sirolimus initiation was 11.7 months (1.6–50.7) and the median time to next treatment (TTNT) was 46.2 months. No patients died at the end of follow-up. Most of the patients in the cohort are in ongoing responses and continue sirolimus therapy. Sirolimus is well tolerated with minor adverse effects. In conclusion, sirolimus is effective for R/R iMCD patients with good tolerance.
- 28 March 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (6) , 631-637
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease
Relapsed and refractory (R/R) idiopathic multicentric Castleman disease (iMCD) is a clinical challenge with no standard treatment. In this preliminary clinical trial, we investigated the efficacy and safety profiles of a Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib, in patients with R/R iMCD. The primary endpoint was the overall response rate at Week 12 according to the Castleman Disease Collaborative Network (CDCN) response criteria. The trial was terminated early due to a lack of treatment response in the first enrolled 5 patients. Although 3 patients achieved symptomatic response, none of the 5 patients had an overall response by Week 12. One patient had progressive disease and the other 4 had stable disease. The study drug was well tolerated without grade 2 or higher adverse events. Our findings suggest that BTKi therapy is not effective for iMCD, and further attempts at single-agent therapy with zanubrutinib or other BTKis for iMCD should be considered with caution and probably avoided. This trial was registered at www.clinialtrials.gov as #NCT04743687.
- 28 March 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (6) , 631-637
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease
Relapsed and refractory (R/R) idiopathic multicentric Castleman disease (iMCD) is a clinical challenge with no standard treatment. In this preliminary clinical trial, we investigated the efficacy and safety profiles of a Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib, in patients with R/R iMCD. The primary endpoint was the overall response rate at Week 12 according to the Castleman Disease Collaborative Network (CDCN) response criteria. The trial was terminated early due to a lack of treatment response in the first enrolled 5 patients. Although 3 patients achieved symptomatic response, none of the 5 patients had an overall response by Week 12. One patient had progressive disease and the other 4 had stable disease. The study drug was well tolerated without grade 2 or higher adverse events. Our findings suggest that BTKi therapy is not effective for iMCD, and further attempts at single-agent therapy with zanubrutinib or other BTKis for iMCD should be considered with caution and probably avoided. This trial was registered at www.clinialtrials.gov as #NCT04743687.
- 15 February 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1830-1837
Idiopathic multicentric Castleman disease (iMCD)‐idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD‐not otherwise specified with different clinical features and better survival
Summary: Idiopathic multicentric Castleman disease (iMCD) is subclassified into iMCD‐thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (TAFRO) and iMCD‐not otherwise specified (NOS) according to the Castleman Disease Collaborative Network (CDCN) consensus criteria. With a deeper understanding of iMCD, a group of patients with iMCD‐NOS characterised by polyclonal hypergammaglobulinaemia, plasmacytic/mixed‐type lymph node histopathology and thrombocytosis has attracted attention. This group of patients has been previously described as having idiopathic plasmacytic lymphadenopathy (IPL). Whether these patients should be excluded from the current classification system lacks sufficient evidence. This retrospective analysis of 228 patients with iMCD‐NOS identified 103 (45.2%) patients with iMCD‐IPL. The clinical features and outcomes of patients with iMCD‐IPL and iMCD‐NOS without IPL were compared. Patients with iMCD‐IPL showed a significantly higher inflammatory state but longer overall survival. No significant difference in overall survival was observed between severe and non‐severe patients in the iMCD‐IPL group according to the CDCN severity classification. Compared with lymphoma‐like treatments, multiple myeloma‐like and IL‐6‐blocking treatment approaches in the iMCD‐IPL group resulted in significantly higher response rates and longer time to the next treatment. These findings highlight the particularities of iMCD‐IPL and suggest that it should be considered a new subtype of iMCD‐NOS.
- 15 February 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1830-1837
Idiopathic multicentric Castleman disease (iMCD)‐idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD‐not otherwise specified with different clinical features and better survival
Summary: Idiopathic multicentric Castleman disease (iMCD) is subclassified into iMCD‐thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (TAFRO) and iMCD‐not otherwise specified (NOS) according to the Castleman Disease Collaborative Network (CDCN) consensus criteria. With a deeper understanding of iMCD, a group of patients with iMCD‐NOS characterised by polyclonal hypergammaglobulinaemia, plasmacytic/mixed‐type lymph node histopathology and thrombocytosis has attracted attention. This group of patients has been previously described as having idiopathic plasmacytic lymphadenopathy (IPL). Whether these patients should be excluded from the current classification system lacks sufficient evidence. This retrospective analysis of 228 patients with iMCD‐NOS identified 103 (45.2%) patients with iMCD‐IPL. The clinical features and outcomes of patients with iMCD‐IPL and iMCD‐NOS without IPL were compared. Patients with iMCD‐IPL showed a significantly higher inflammatory state but longer overall survival. No significant difference in overall survival was observed between severe and non‐severe patients in the iMCD‐IPL group according to the CDCN severity classification. Compared with lymphoma‐like treatments, multiple myeloma‐like and IL‐6‐blocking treatment approaches in the iMCD‐IPL group resulted in significantly higher response rates and longer time to the next treatment. These findings highlight the particularities of iMCD‐IPL and suggest that it should be considered a new subtype of iMCD‐NOS.